Navigation Links
One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
Date:10/27/2008

a tendon, ligament or joint capsule insertion to the bone, and dactylitis, a swelling of digits in the hands or feet, are estimated to affect more than one-third of people with psoriatic arthritis.

The Biologics License Application (BLA) and Marketing Authorization Application (MAA) for golimumab were submitted earlier in the year and are currently under review by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA), respectively. The filings are based on the extensive clinical development program for golimumab, including data from five pivotal Phase 3 trials in rheumatoid arthritis (RA), psoriatic arthritis and ankylosing spondylitis.

About the GO-REVEAL Trial

The GO-REVEAL trial involved 405 adults with psoriatic arthritis. Subjects with at least three swollen and tender joints and active psoriatic skin lesions of at least 2 centimeters in diameter were randomly assigned to receive subcutaneous injections of placebo or golimumab (50 or 100 mg) at week 0 and every 4 weeks thereafter through the end of the study. At week 16, patients with inadequate arthritis response were switched to golimumab 50 mg (patients originally receiving placebo) or golimumab 100 mg (patients originally receiving golimumab 50 mg). At week 24 all placebo patients crossed over to active treatment with golimumab 50 mg. The primary endpoint was ACR 20 response at week 14 for combined golimumab groups and individual golimumab dose groups versus placebo.

Through week 24, the placebo-controlled portion of the study, 2 percent of golimumab-treated patients experienced serious adverse events (SAE) compared with 6 percent of patients in the placebo group. Injection site reactions (ISR) occurred in 5 percent of patients receiving golimumab and 3 percent of patients receiving placebo. One case of prostate cancer and 2 cases of basal cell carcinoma were reported in golimumab-treated patients. Through week 52, 5 percent of golimumab-treated pat
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
2. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. In-Room Computers and Wall-Mounted Proximity Systems Computer WorkStations Deliver Increased Efficiency; Improved Patient Care
5. Finesse Solutions Launches Improved E-Store for Sensors and Transmitters
6. Kelly Osbourne and International Health Groups Call for Improved Education on Choices and Usage of Contraception
7. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
8. Improved culture system for hepatitis C virus infection
9. Pharmacy Students Taught Improved Medication Adherence and Holistic Health Services Through Program Incorporating InforMedixs Med-eXpert(TM) System
10. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
11. China Kangtai Cactus Biotech Announces Improved Milk Production in Cows From Companys Cactus Cattle Feed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... BioSciences, Inc. (NASDAQ: SGMO ) announced today that ... update on the progress of Sangamo,s ZFP Therapeutic ® ... at 1:30pm ET on Monday, June 1, 2015, at the ... in New York, NY . ... via a link on the Sangamo BioSciences website in the ...
(Date:5/26/2015)... 26, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... Company,s Annual Meeting of Shareholders for fiscal year ended ... at the Company,s office located in Chengdu, ... AM (local time in Chengdu, China ...
(Date:5/26/2015)... 2015   PDI , a leader in ... Oakwood Healthcare in Dearborn, Mich. ... in Delivering the Difference , ... in building collaborative relationships between infection prevention (IP) ... Oakwood Healthcare,s infection preventionist, ...
(Date:5/26/2015)... Diego, CA (PRWEB) May 26, 2015 ... announced the beginning of a long-term relationship with ... on behalf of its members to provide access ... am extremely pleased to count VGP as a ... more arthritic dog patients nationwide. Concentrating and using ...
Breaking Biology Technology:Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 3PDI Announces Winner in Delivering the Difference Contest 2PDI Announces Winner in Delivering the Difference Contest 3VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering 2VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering 3
... Aug. 14 /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, ... Company,) (Amex: CSY ), a,leading fully ... in the People,s Republic of China ("PRC"), ... spray for the treatment,and prevention of rheumatic ...
... Technology ... ... (Nasdaq: PRXL ), a leading global biopharmaceutical services,organization, today ... leading clinical technology organization. By combining,ClinPhone with Perceptive Informatics, PAREXEL,s ...
... to Host Conference Call at 4:30 p.m. ET Today -, ... ) today reported financial results for its fourth quarter,and fiscal ... fourth quarter of,fiscal 2008 was $4.6 million, or $0.18 per ... per share, for the fourth quarter of fiscal 2007., ...
Cached Biology Technology:China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease 2China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease 3PAREXEL Closes the Acquisition of ClinPhone 2PAREXEL Closes the Acquisition of ClinPhone 3PAREXEL Closes the Acquisition of ClinPhone 4PAREXEL Closes the Acquisition of ClinPhone 5Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 2Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 3Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 4Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 5Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 6
(Date:4/27/2015)... 27, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... customers the first week of May, 2015 and will ... May. Gino Pereira , Chief ... the company as Wocket® enters the consumer market. We ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial ... Valley to implant a new miniaturized, wireless monitoring sensor ... is the first and only FDA-approved heart failure monitoring ... admissions when used by physicians to manage heart failure. ... that is implanted in the pulmonary artery (PA) during ...
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... , June 11, 2013 Intelligent building industry ... costing (LCC) as a valid prerequisite in the process ... presently, use of LCC to determine long-term return on ... are a long-term commitment in most cases, making well-informed ...
... (HCV) infects more than 170 million people worldwide. Approximately ... fibrosis, cirrhosis, cancer and also hepatic iron overload. A ... Stritch School of Medicine reveals that HCV not only ... receptor 1 (TfR1) but that TfR1 also mediates HCV ...
... than a decade, scientists have suspected that hairpin-shaped chains of ... NC State University have found the first example and mapped ... research, published online in Proceedings of the National Academy ... one strand of micro-RNA reduced by more than 20 percent ...
Cached Biology News:A Future-Proof Approach to Intelligent Buildings 2A Future-Proof Approach to Intelligent Buildings 3A Future-Proof Approach to Intelligent Buildings 4New Loyola study on hepatitis C virus entry factor 2
... UNIchip AV-400 contains 400 unique ... nitrocellulose-coated glass slide. The proteins, a ... are arrayed in quadruplicate for high-quality ... specific chip layout guarantee high validity ...
... UNIchip AV-400 contains 400 unique human ... glass slide. The proteins, all extracellular ... classification, are arrayed in quadruplicate for ... a specific chip layout guarantee high ...
... Sub-Plates are E.Coli glycerol stocks contained in ... 50 cDNA clones with approximately 5,000 clones ... a master plate well, the corresponding subplate ... to identify the positive well(s). Cells from ...
... Lysate Systems(a,b,c,d) offer researchers an alternative ... single-tube, coupled transcription/translation system. The TNT ... and reduce the time required to ... rabbit reticulocyte lysate translations (1) commonly ...
Biology Products: